Int J Cardiol:Takotsubo综合征患者的入院心率与住院病程

2018-08-03 xing.T MedSci原创

由此可见,在患有TS的大型人群中,入院时较高的HR可独立预测复杂的住院病程。

Takotsubo综合征(TS)患者住院病程长短不一,并且危及生命的并发症在急性期并不少见。在这种情况下,心率(HR)作为预后预测因子的作用尚未得到充分研究。近日,心血管领域权威杂志International Journal of Cardiology上发表了一篇研究文章,该研究旨在评估就诊时的HR对TS患者住院病程长短的影响。

研究人群包含221名参加多中心登记的TS患者。入院时的HR是通过第一次心电图进行评估。根据HR的三分位数分布,受试者被分为3组:A组(HR≤76次/分钟(bpm),n=76),B组(HR 77-95bpm,n=74)和C组(HR>95bpm,n=71)。急性住院并发症定义为严重泵衰竭和严重心律失常。

32名(14.4%)患者经历了复杂的院内病程。与没有并发症的患者相比,发生并发症的患者入院时HR明显较高(108bpm vs. 85bpm; p<0.001),射血分数(EF)较低(35% vs. 40%; p=0.009)。与A组和B组相比,C组患者的并发症发生率高5倍。多变量分析发现较高的HR(HR每增加10bpm的比值比为1.34,95%置信区间(CI)为1.12-1.59; p=0.001)和较低的EF(EF每降低5%比值比为1.24,95%CI为1.01-1.54; p=0.049)仍与更差的结局独立相关。

由此可见,在患有TS的大型人群中,入院时较高的HR可独立预测复杂的住院病程。

原始出处:

LucaArcari,et al. Admission heart rate and in-hospital course of patients with Takotsubo syndrome.International Journal of Cardiology.2018. https://doi.org/10.1016/j.ijcard.2018.07.145

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781931, encodeId=26991e8193112, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue May 07 08:19:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431294, encodeId=a7601431294e9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590578, encodeId=657215905e836, content=<a href='/topic/show?id=53691e108c5' target=_blank style='color:#2F92EE;'>#Takotsubo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17108, encryptionId=53691e108c5, topicName=Takotsubo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04c017833400, createdName=axin015, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336058, encodeId=ff08336058a6, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Aug 03 17:25:27 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336047, encodeId=435d33604e37, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 03 16:45:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781931, encodeId=26991e8193112, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue May 07 08:19:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431294, encodeId=a7601431294e9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590578, encodeId=657215905e836, content=<a href='/topic/show?id=53691e108c5' target=_blank style='color:#2F92EE;'>#Takotsubo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17108, encryptionId=53691e108c5, topicName=Takotsubo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04c017833400, createdName=axin015, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336058, encodeId=ff08336058a6, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Aug 03 17:25:27 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336047, encodeId=435d33604e37, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 03 16:45:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781931, encodeId=26991e8193112, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue May 07 08:19:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431294, encodeId=a7601431294e9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590578, encodeId=657215905e836, content=<a href='/topic/show?id=53691e108c5' target=_blank style='color:#2F92EE;'>#Takotsubo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17108, encryptionId=53691e108c5, topicName=Takotsubo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04c017833400, createdName=axin015, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336058, encodeId=ff08336058a6, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Aug 03 17:25:27 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336047, encodeId=435d33604e37, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 03 16:45:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
    2018-08-05 axin015
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781931, encodeId=26991e8193112, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue May 07 08:19:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431294, encodeId=a7601431294e9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590578, encodeId=657215905e836, content=<a href='/topic/show?id=53691e108c5' target=_blank style='color:#2F92EE;'>#Takotsubo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17108, encryptionId=53691e108c5, topicName=Takotsubo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04c017833400, createdName=axin015, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336058, encodeId=ff08336058a6, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Aug 03 17:25:27 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336047, encodeId=435d33604e37, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 03 16:45:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
    2018-08-03 1e0f8808m18(暂无匿称)

    好文章,学习了。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1781931, encodeId=26991e8193112, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue May 07 08:19:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431294, encodeId=a7601431294e9, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590578, encodeId=657215905e836, content=<a href='/topic/show?id=53691e108c5' target=_blank style='color:#2F92EE;'>#Takotsubo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17108, encryptionId=53691e108c5, topicName=Takotsubo)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04c017833400, createdName=axin015, createdTime=Sun Aug 05 04:19:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336058, encodeId=ff08336058a6, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Aug 03 17:25:27 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336047, encodeId=435d33604e37, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Aug 03 16:45:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
    2018-08-03 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

相关资讯

JACC:Takotsubo综合征发病机制的研究

Takotsubo综合征(TTS)是一种急性左室功能不全,并且急性期可能会致命的临床综合征。目前,TTS的发病机制尚未阐明。近日,在国际心血管权威杂志JACC上发表了一篇旨在建立TTS体外引导性多能干细胞(IPSC)模型以研究儿茶酚胺-β信号通路是否在IPSC-心肌细胞(CMs)有所改变,并探究其机制的研究。本研究将TTS患者和正常对照的体细胞提取,诱导为IPSC,并分化为心肌细胞。三个月大的心肌

Diabetes Care:Takotsubo综合征患者糖尿病的患病率和预后影响!

由此可见,TTS患者中糖尿病并不常见,它与长期死亡率增加有关,并且与其他危险因素无关,是预后不良的独立预测因子。